Physician profile

Eric L Smith

Adult Reconstructive Orthopaedic Surgery · Boston, MA

NPI 1306859442

$648,992.28

in general payments reported to CMS, 2019-2025

26 companies · $203K in 2025

The $203K reported for 2025 was more than what 95% of Adult Reconstructive Orthopaedic Surgery providers received nationally (typical 2025 total: $1,425).

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Royalty Or License$178,450.05
Consulting Fee$109,232.73
Travel and Lodging$24,058.38
Food and Beverage$6,434.86
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$4,638.80
Honoraria$2,275.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Depuy Synthes Products, INC. $281,764.22 2021-2025 Velys, Pinnacle, Corail
Medical Device Business Services, INC. $189,711.32 2019-2025 Attune, Actis, Velys
Conformis, INC. $133,299.39 2019-2023 Itotal Identity Cruciate Retaining Knee Replacement System
Pacira Therapeutics, INC. $15,727.18 2020-2021
Medacta USA, INC. $9,511.21 2019-2025 Amistem, Gmk Revision, Gmk Efficiency
Pacira Pharmaceuticals Incorporated $9,461.36 2020-2025 Iovera, Exparel, Zilretta
Restor3d, INC. $4,387.36 2023-2025
Zimmer Biomet Holdings, INC. $962.40 2020-2025 Persona, Oss Orthopedic Salvage System, Tapestry
Stryker Corporation $959.38 2020-2025 Mako, T2 Alpha, Exeter
Depuy Synthes Sales INC. $886.82 2019-2025 Attune, Velys, Emphasys
Bioventus LLC $601.84 2021-2023 Durolane
Smith+Nephew, INC. $532.65 2020-2023 Ri Hip Navigation, Journey II, Or3o Dual Mobility
Heron Therapeutics, INC. $296.31 2021-2024 Zynrelef
Exactech, INC. $165.80 2021-2023
Wishbone Medical INC. $150.07 2023
Show all 25 companies
CompanyGeneral paymentsYearsTop products
Onkos Surgical, INC. $137.57 2021-2025 Eleos Limb Salvage System
Banner Surgical Solutions, INC $126.71 2025
Baudax Bio INC. $79.39 2021-2022
Ferring Pharmaceuticals INC. $60.37 2020-2021
Convatec INC. $53.01 2021
Pfizer INC. $43.72 2019-2023
Encore Medical, LP $22.47 2020
Heraeus Medical, LLC. $21.17 2020
Sanofi-Aventis U.S. LLC $17.37 2023
Radius Health, INC. $13.19 2022

1 company reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$5,000.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Eric L Smith

$648,992.28

in general payments reported 2019-2025

Years
2019-2025
Top company
Depuy Synthes Products, INC.
Context
The $203K reported for 2025 was more than what 95% of Adult Reconstructive Orthopaedic Surgery providers received nationally (typical 2025 total: $1,425).

https://glasscript.com/doctor/149604/eric-l-smith

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.